Register For Our Mailing List

Register to receive our free weekly newsletter including editorials.

Home / 227

What’s driving the recent Small Ords surge?

The S&P/ASX Small Ordinaries Index (ASX Small Ords) has surged by over 10% in the last three months on a seemingly new upward trajectory despite what was a fairly mixed reporting season. For the month of October 2017 alone, the Index delivered a gain of 6%.

While the return looks impressive, closer analysis shows that this surge in the Small Ords has been led mainly by concept and momentum stocks, a rather narrow foundation. Leading the charge upwards has been the small cap resource sector, several technology stocks and ‘soft commodity’ plays with exposure to China. We refer to them as ‘concept ‘stocks.

The table below highlights the valuations, free cash flow produced as well as these concept stocks’ contribution to the Small Ords performance over the last three months.

Recent key movers on the S&P/ASX Small Ordinaries Index (Small Ords)

Based on share prices at 31 October 2017

Some interesting facts:

 

  • While the Small Ords Index was up 10.3% for the three months to 31 October 2017, these 13 stocks accounted for over half of that return.

 

 

  • This group accounts for $24.4 billion of market capitalisation. This market cap is expected to generate an aggregate of $571 million of reported profit in FY18e - on average a PE of over 40x forecast 2018 earnings and a forecast dividend yield of 1%.

 

 

  • In addition, these companies are expected to generate an aggregate Free Cash Flow of MINUS $76.6 million or a free cash yield of MINUS 0.3%.

 

 

What does this mean for the rest of the market and for prudent long-term investors?

It appears that in the current market, fundamentals have taken a back seat to momentum, unbounded optimism and the fear of missing out on the next big thing.

On the other hand, quality well-established companies that may have any sort of short-term earnings concerns are being sold down regardless of value. While this is creating great opportunities to buy quality stocks at attractive prices, it is hurting the performance of fundamentally based portfolios such as IML’s, particularly given our distinct preference for stocks that meet our quality and value criteria as opposed to concept type stocks.

In the table below are examples of long-established, good quality companies and their fundamentals. The share prices of these companies have actually gone backwards in the last three months.

Based on share prices at 31 October 2017

We believe investors should focus on the long term and not to get caught up the latest market fad, particularly at times like this when momentum and optimism has taken hold of some sections of the Australian sharemarket. By investing in companies that demonstrate strong competitive advantage, recurring revenues, with long term growing earnings and that are trading at reasonable prices, more consistent investment returns are expected over the longer term.

 

Anton Tagliaferro is Investment Director and Simon Conn is Senior Portfolio Manager at Investors Mutual Limited. This information is general in nature and has been prepared without taking into account of the objectives, financial situation or needs of any investor.

 

RELATED ARTICLES

Thinking small to win big

Why have small cap stocks underperformed?

banner

Most viewed in recent weeks

Vale Graham Hand

It’s with heavy hearts that we announce Firstlinks’ co-founder and former Managing Editor, Graham Hand, has died aged 66. Graham was a legendary figure in the finance industry and here are three tributes to him.

Australian stocks will crush housing over the next decade, one year on

Last year, I wrote an article suggesting returns from ASX stocks would trample those from housing over the next decade. One year later, this is an update on how that forecast is going and what's changed since.

Avoiding wealth transfer pitfalls

Australia is in the early throes of an intergenerational wealth transfer worth an estimated $3.5 trillion. Here's a case study highlighting some of the challenges with transferring wealth between generations.

Taxpayers betrayed by Future Fund debacle

The Future Fund's original purpose was to meet the unfunded liabilities of Commonwealth defined benefit schemes. These liabilities have ballooned to an estimated $290 billion and taxpayers continue to be treated like fools.

Australia’s shameful super gap

ASFA provides a key guide for how much you will need to live on in retirement. Unfortunately it has many deficiencies, and the averages don't tell the full story of the growing gender superannuation gap.

Looking beyond banks for dividend income

The Big Four banks have had an extraordinary run and it’s left income investors with a conundrum: to stick with them even though they now offer relatively low dividend yields and limited growth prospects or to look elsewhere.

Latest Updates

Investment strategies

9 lessons from 2024

Key lessons include expensive stocks can always get more expensive, Bitcoin is our tulip mania, follow the smart money, the young are coming with pitchforks on housing, and the importance of staying invested.

Investment strategies

Time to announce the X-factor for 2024

What is the X-factor - the largely unexpected influence that wasn’t thought about when the year began but came from left field to have powerful effects on investment returns - for 2024? It's time to select the winner.

Shares

Australian shares struggle as 2020s reach halfway point

It’s halfway through the 2020s decade and time to get a scorecheck on the Australian stock market. The picture isn't pretty as Aussie shares are having a below-average decade so far, though history shows that all is not lost.

Shares

Is FOMO overruling investment basics?

Four years ago, we introduced our 'bubbles' chart to show how the market had become concentrated in one type of stock and one view of the future. This looks at what, if anything, has changed, and what it means for investors.

Shares

Is Medibank Private a bargain?

Regulatory tensions have weighed on Medibank's share price though it's unlikely that the government will step in and prop up private hospitals. This creates an opportunity to invest in Australia’s largest health insurer.

Shares

Negative correlations, positive allocations

A nascent theme today is that the inverse correlation between bonds and stocks has returned as inflation and economic growth moderate. This broadens the potential for risk-adjusted returns in multi-asset portfolios.

Retirement

The secret to a good retirement

An Australian anthropologist studying Japanese seniors has come to a counter-intuitive conclusion to what makes for a great retirement: she suggests the seeds may be found in how we approach our working years.

Sponsors

Alliances

© 2024 Morningstar, Inc. All rights reserved.

Disclaimer
The data, research and opinions provided here are for information purposes; are not an offer to buy or sell a security; and are not warranted to be correct, complete or accurate. Morningstar, its affiliates, and third-party content providers are not responsible for any investment decisions, damages or losses resulting from, or related to, the data and analyses or their use. To the extent any content is general advice, it has been prepared for clients of Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), without reference to your financial objectives, situation or needs. For more information refer to our Financial Services Guide. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Articles are current as at date of publication.
This website contains information and opinions provided by third parties. Inclusion of this information does not necessarily represent Morningstar’s positions, strategies or opinions and should not be considered an endorsement by Morningstar.